NCT02862171View on ClinicalTrials.gov

To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women

PHASE3CompletedINTERVENTIONAL

Enrollment

941

Participants

Timeline

Start Date

July 12, 2016

Primary Completion Date

January 11, 2019

Study Completion Date

January 11, 2019

Conditions

HIV Prevention

Interventions

DRUG

Dapivirine Vaginal Ring-004

To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial

Trial Locations (6)

3216

MatCH Research Unit, Pietermaritzburg

3370

Qhakaza Mbokodo, Ladysmith

7675

Desmond Tutu HIV Foundation, Cape Town

0250

Madibeng Centre for Research, Brits

Unknown

Ndlovu Medical Centre, Elandsdoorn

MRC/UVRI Uganda Research Unit on AIDS, Entebbe

All Listed Sponsors

lead

International Partnership for Microbicides, Inc.

INDUSTRY

NCT02862171 - To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women | Biotech Hunter | Biotech Hunter